跳至主要内容
临床试验/NCT00231348
NCT00231348已完成4 期

Nefazodone in the Treatment of Social Phobia: Functional Brain Imaging and Neuroendocrine Correlates

Emory University2 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2005年10月4日最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
24
试验地点
2

研究概览

简要总结

The purpose of this study is to determine the effectiveness of nefazadone in patients with social anxiety disorder (SAD).

详细描述

The purpose of this study is to examine the efficacy of the 5HT2 receptor antagonist nefazadone in SAD, and to explore regional cerebral blood flow in patients with SAD when confronted with a personal phobic stimulus, using positron emission tomography (PET). Changes in cerebral blood flow were correlated with self-rated anxiety measures.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • DSM-IV diagnosis of generalized social anxiety disorder, males and females between the ages of 18-65

排除标准

  • A history of bipolar disorder, psychotic illness, or any other anxiety disorders, organic brain disease or active drug or alcohol abuse within one year as assessed by the SCID-P and interview, or a concurrent medical condition that would not be compatible with the study in the opinion of the principal investigator. Patients required to be free of psychotropic or beta-blocker medication for 2 weeks prior to study. Pts taking fluoxetine required to be drug-free for 6 weeks.

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验